Experimental models for evaluating non-genomic estrogen signaling.

Steroids

Receptor Biology Section, Reproductive and Developmental Biology Laboratory, National Institutes of Health, NIEHS, 111 TW Alexander Dr, Research Triangle Park, NC 27709, USA. Electronic address:

Published: May 2018

Non-genomic effects of estrogen receptor α (ERα) signaling have been described for decades. However, the mechanisms and physiological processes resulting solely from non-genomic signaling are poorly understood. Challenges in studying these effects arise from the strongly nucleophilic tendencies of estrogen receptor, and many approaches to excluding ERα from the nucleus have been explored over the years. In this review, we discuss past strategies for studying ERα's non-genomic action and current models, specifically H2NES ERα, first described by Burns et al. (2011). In vitro and preliminary in vivo data from H2NES ERα and H2NES mice suggest a promising avenue for pinpointing specific non-genomic ERα action.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864539PMC
http://dx.doi.org/10.1016/j.steroids.2017.11.001DOI Listing

Publication Analysis

Top Keywords

estrogen receptor
8
h2nes erα
8
non-genomic
5
erα
5
experimental models
4
models evaluating
4
evaluating non-genomic
4
non-genomic estrogen
4
estrogen signaling
4
signaling non-genomic
4

Similar Publications

Background: Vulvodynia is a multifactorial disease affecting 7%-16% of reproductive-aged women in general population; however, little is still known about the genetics underlying this complex disease.

Aim: To compare polygenic risk scores for hormones and receptors levels in a case-control study to investigate their role in vulvodynia and their correlation with clinical phenotypes.

Methods: Our case-control study included patients with vestibulodynia (VBD) and healthy women.

View Article and Find Full Text PDF

Hormonal factors play an essential role as an underlying causative factor of oligoasthenoteratozoospermia (OAT), and these patients can benefit from hormonal medications that modulate the hypothalamic-pituitary-gonadal axis. This review aims to outline the various medications used as hormonal therapy in treating infertile men with OAT. This manuscript focuses on essential hormonal evaluation, identifying men who would benefit from treatment, selecting the appropriate medication, determining the duration of therapy, and evaluating hormonal treatment outcomes.

View Article and Find Full Text PDF

Background: Proteasomes degrade intracellular proteins. Different proteasome forms were identified. Proteasome inhibitors are used in cancer therapy, and novel drugs directed to specific proteasome forms are developed.

View Article and Find Full Text PDF

: Fructus (AOF) is a medicinal and edible resource that holds potential to ameliorate hyperuricemia (HUA), yet its mechanism of action warrants further investigation. : We performed network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experiments to investigate the potential action and mechanism of AOF against HUA. : The results indicate that 48 potential anti-HUA targets for 4 components derived from AOF were excavated and predicted through public databases.

View Article and Find Full Text PDF
Article Synopsis
  • Ovarian cancer is a major cause of cancer-related deaths in women, with both genetic and epigenetic factors contributing to its development and progression.
  • Estrogen signaling plays a significant role in ovarian cancer, involving estrogen receptors and their regulation of genes related to cell growth and death, influenced by epigenetic changes like histone modifications and DNA methylation.
  • This review summarizes current knowledge on these epigenetic mechanisms and explores the potential of epigenetic therapies as treatment options for ovarian cancer.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!